论文部分内容阅读
急性缺血性卒中是目前导致人类死亡的三大主要疾病之一,具有高发病率、高致残率、高病死率的特点。目前急性期的治疗方法主要有建立卒中单元、抗血小板聚集、抗凝、降纤等,但疗效并不理想。而早期动脉溶栓治疗时是目前被认可的有效的治疗措施,但因存在治疗间窗过窄和诸多并发症的问题,只有少部分的卒中患者接受了溶栓治疗。所以选择最佳的溶栓时机、溶栓剂和减少并发症的发生是溶栓治疗的关键。
Acute ischemic stroke is one of the three major diseases that cause human death at present, with high morbidity, high morbidity and high mortality. The current treatment of acute phase mainly to establish a stroke unit, anti-platelet aggregation, anticoagulation, fibrinolysis, but the effect is not satisfactory. However, early arterial thrombolysis is an accepted and effective treatment. However, only a small number of stroke patients receive thrombolytic therapy because of the narrowing of the treatment window and complications. So choose the best timing of thrombolysis, thrombolytic agents and reduce the incidence of complications is the key to thrombolytic therapy.